{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:56:28Z","timestamp":1788821788345,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>The diagnosis of uterine smooth muscle tumors is sometimes difficult, as these tumors may show worrisome features, suspicious for but not diagnostic of malignancy. The recommended immunohistochemical panel in this setting is currently under debate. In this study, we aimed to find a panel of immunohistochemical stains that would be helpful in determining the correct diagnosis in ambiguous uterine smooth muscle tumors, with an emphasis on investigating the possible usefulness of the WT1 antibody. Uterine leiomyomas were found to be immunoreactive with WT1. Since a previous study reported on the lack of immunoreactivity of uterine leiomyosarcomas with WT1, we speculated that WT1 might be useful in this setting. We retrospectively reviewed the medical charts and slides of 91 patients: 22 with leiomyosarcoma, 15 with smooth muscle tumor of uncertain malignant potential, and 54 with leiomyoma. Immunohistochemical stains for WT1, p16, p53, and Ki67 were performed on each case. We found that immunoreactivity with p16 and Ki67 (&gt;40% and &gt;10% of the tumor cells, respectively) and loss of nuclear expression of WT1 (&lt;10% of the tumor cells) were significantly more common in leiomyosarcomas (all <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Mutated p53 immunohistochemical staining pattern was significantly more prevalent in leiomyosarcomas than in leiomyomas (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Thus, in diagnostically challenging uterine smooth muscle tumors, we recommend using an immunohistochemical panel composed of Ki67, p16, p53, and WT1. A positive result in either of the former 2 (p16 &gt;40% and\/or Ki67 &gt;10%) has the strongest association with leiomyosarcoma (sensitivity: 95.5%, specificity=88.9%, positive predictive value=77.8%, negative predictive value=98.0%).<\/jats:p>","DOI":"10.1097\/pgp.0000000000000688","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T17:00:34Z","timestamp":1599411634000},"page":"257-262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases"],"prefix":"10.1097","volume":"40","author":[{"given":"Bertha","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Dreiher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Braiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthy","family":"Shaco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"R1-20250802","first-page":"555","article-title":"Wilms\u2019 tumor as a paradigm for the relationship of cancer to development","volume":"9","author":"Pritchard-Jones","year":"1990","journal-title":"Cancer Surv"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0959-437X(93)90113-4","article-title":"Wilms\u2019 tumor gene and function","volume":"3","author":"Hastie","year":"1993","journal-title":"Curr Opin Genet Dev"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/346194a0","article-title":"The candidate Wilms\u2019 tumor gene is involved in genitourinary development","volume":"346","author":"Pritchard-Jones","year":"1990","journal-title":"Nature"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/mp.50.3.138","article-title":"Expression of the Wilms\u2019 tumor gene WT1 in the developing human and in pediatric renal tumors: an immunohistochemical study","volume":"50","author":"Charles","year":"1997","journal-title":"Mol Pathol"},{"key":"R5-20250802","first-page":"344","article-title":"Wilms\u2019 tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma","volume":"146","author":"Amin","year":"1995","journal-title":"Am J Pathol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004347-200004000-00010","article-title":"Immunohistochemical detection of the Wilms\u2019 tumor gene (WT1) in epithelial ovarian tumors","volume":"19","author":"Shimizu","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.pgp.0000130051.04396.13","article-title":"Endometrial stromal neoplasms are immunoreactive with WT1 antibody","volume":"23","author":"Sumathi","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ejca.2007.04.008","article-title":"Upregulation of Wilms\u2019 tumor gene 1 (WT1) in uterine sarcomas","volume":"43","author":"Coosemans","year":"2007","journal-title":"Eur J Cancer"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00129039-200106000-00009","article-title":"Immunohistochemical distinction of endometrial stromal sarcoma and cellular leimyoma","volume":"9","author":"Agoff","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/modpathol.2009.122","article-title":"A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors","volume":"22","author":"Lee","year":"2009","journal-title":"Mod Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/PAS.0b013e3181a02d1c","article-title":"Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases","volume":"33","author":"Ip","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/PAP.0b013e3181cfb901","article-title":"Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy","volume":"17","author":"Ip","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PGP.0b013e31815ea7f5","article-title":"Immunohistochemical analysis of p16, p53, and Ki67 expression in uterine smooth muscle tumors","volume":"27","author":"Chen","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2559.2007.02699.x","article-title":"Uterine leiomyosarcomas are characterized by a high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumors of uncertain malignant potential","volume":"50","author":"O\u2019Neill","year":"2007","journal-title":"Histopathology"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2004.09.026","article-title":"Expression of P16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis","volume":"96","author":"Bodner-Adler","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0b013e3181574d1e","article-title":"The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors","volume":"32","author":"Atkins","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-7-1","article-title":"Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors","volume":"7","author":"Hewedi","year":"2012","journal-title":"Diagn Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.1999.5436","article-title":"Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases","volume":"74","author":"Mayerhofer","year":"1999","journal-title":"Gynecol Oncol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0968-6053(03)00072-3","article-title":"Uterine smooth muscle tumours: practical approach to diagnosis","volume":"10","author":"Al-Nafussi","year":"2004","journal-title":"Curr Diagn Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/PAS.0b013e318287779c","article-title":"Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma. Immunohistochemical study of 68 cases with clinical follow-up","volume":"37","author":"Mills","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R23-20250802","first-page":"7196","article-title":"Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma","volume":"8","author":"Yun","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"E1136","DOI":"10.3390\/ijms20051136","article-title":"The usefulness of immunohistochemistry in the differential diagnosis of lesions originating from the myometrium","volume":"20","author":"Rubisz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R25-20250802","first-page":"513","article-title":"Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors","volume":"32","author":"Hakverdi","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000080933","article-title":"Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and rogesterone receptors","volume":"59","author":"G\u00f6kaslan","year":"2005","journal-title":"Gynecol Obstet Invest"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.pap.0000201828.92719.f3","article-title":"P16 expression in the female genital tract and its value in diagnosis","volume":"13","author":"O\u2019Neill","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00004347-199901000-00004","article-title":"Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas","volume":"18","author":"Zhai","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0046-8177(95)90136-1","article-title":"P53 protein overxpression in smooth muscle tumors of the uterus","volume":"26","author":"Niemann","year":"1995","journal-title":"Hum Pathol"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAS.0b013e318208e361","article-title":"Inguinal smooth muscle tumors in women\u2014a dichotomous group consisting of M\u00fcllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases","volume":"35","author":"Patil","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/PGP.0b013e31824d3539","article-title":"Low-grade smooth muscle tumors of the primary and the secondary mullerian system: a proposed concept of multicentricity","volume":"31","author":"Posligua","year":"2012","journal-title":"Int J Gynecol Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:04:27Z","timestamp":1754161467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000688","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}